Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomes
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-018-3712-7
Abstract: PurposeIn this study, we aimed to describe the real-life practice outcomes of pertuzumab–trastuzumab–taxane (PTT) combination in visceral organ metastatic, trastuzumab-naive breast cancer (BC) patients.MethodsThis study was conducted by Turkish Oncology Group and included 317 patients’… read more here.
Keywords: pertuzumab trastuzumab; trastuzumab taxane; metastatic trastuzumab; taxane ... See more keywords
Pharmacokinetic and exposure–response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-019-03871-w
Abstract: PurposeTo characterize the pharmacokinetics (PK) of pertuzumab and trastuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer in the randomized, double-blind, phase III JACOB study (NCT01774786), and to evaluate the appropriateness of the… read more here.
Keywords: pertuzumab trastuzumab; patients her2; her2 positive; pertuzumab ... See more keywords
Real-world effectiveness of dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer (The NEOPETRA Study)
Sign Up to like & getrecommendations! Published in 2020 at "Breast Cancer Research and Treatment"
DOI: 10.1007/s10549-020-05866-1
Abstract: Neoadjuvant clinical trials with dual HER2 blockade with pertuzumab and trastuzumab plus chemotherapy demonstrated high rates of pathological complete response (pCR) in HER2-positive early breast cancer (BC). We investigated whether the benefit on pCR seen… read more here.
Keywords: her2; pertuzumab trastuzumab; her2 positive; breast ... See more keywords
Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study
Sign Up to like & getrecommendations! Published in 2018 at "Annals of Oncology"
DOI: 10.1093/annonc/mdx773
Abstract: Abstract Background Anti-HER2 therapies are associated with a risk of increased cardiac toxicity, particularly when part of anthracycline-containing regimens. We report cardiac safety of pertuzumab, trastuzumab, and chemotherapy in the neoadjuvant treatment of HER2-positive early… read more here.
Keywords: cardiac safety; pertuzumab trastuzumab; neoadjuvant treatment; treatment ... See more keywords
Pertuzumab, Trastuzumab, and an Aromatase Inhibitor for HER2-Positive and Hormone Receptor–Positive Metastatic or Locally Advanced Breast Cancer: PERTAIN Final Analysis
Sign Up to like & getrecommendations! Published in 2023 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-22-1092
Abstract: Abstract Purpose: In PERTAIN's primary analysis (31 months’ median follow-up), adding pertuzumab to trastuzumab and an aromatase inhibitor (AI) with/without chemotherapy significantly improved progression-free survival (PFS) in patients with previously untreated HER2-positive and hormone receptor–positive… read more here.
Keywords: pertuzumab trastuzumab; final analysis; pertuzumab; analysis ... See more keywords
Abstract PS13-39: Efficacy and tolerability of neoadjuvant Pertuzumab, Trastuzumab, and weekly Paclitaxel in Locally advanced Her-2 positive Breast cancer
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Research"
DOI: 10.1158/1538-7445.sabcs20-ps13-39
Abstract: Background:Administration of neoadjuvant Pertuzumab (P), trastuzumab (T) along with chemotherapy is the standard of care for the management of locally advanced/inflammatory Her-2 positive breast cancer. Neutropenia and diarrhea are often the significant side-effects observed with… read more here.
Keywords: locally advanced; weekly paclitaxel; cancer; breast cancer ... See more keywords
Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive breast cancer: A multidisciplinary approach
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Oncology Pharmacy Practice"
DOI: 10.1177/1078155221999712
Abstract: Pertuzumab plus trastuzumab, administered intravenously (IV) with chemotherapy, is standard treatment for HER2-positive metastatic or high-risk early breast cancer. Pertuzumab and trastuzumab are administered over 1–2.5 h traditionally; however, the need for IV infusions places a… read more here.
Keywords: pertuzumab; pertuzumab trastuzumab; her2 positive; breast cancer ... See more keywords
A Locally Advanced Breast Cancer that Achieved pCR with Pertuzumab, Trastuzumab and Docetaxel: Case Report.
Sign Up to like & getrecommendations! Published in 2017 at "Anticancer research"
DOI: 10.21873/anticanres.11530
Abstract: We herein report a case of locally advanced human epidermal growth factor receptor 2 (HER2)-positive breast cancer that achieved a pathological complete response (pCR) with pertuzumab, trastuzumab and docetaxel therapy. A 70-year-old female presented with… read more here.
Keywords: pertuzumab trastuzumab; breast; breast cancer; locally advanced ... See more keywords
BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14112596
Abstract: Simple Summary A combination of pertuzumab, trastuzumab, and chemotherapy is a standard treatment for patients with a type of breast cancer called HER2-positive. Before the BERENICE study, little was known about the safety and effectiveness… read more here.
Keywords: cardiac safety; her2 positive; pertuzumab; pertuzumab trastuzumab ... See more keywords